Acumen Pharmaceuticals, Inc. develops clinical-stage Alzheimer’s disease therapeutics that target toxic soluble amyloid beta oligomers. The company’s recurring updates center on sabirnetug (ACU193), a humanized monoclonal antibody program, the ALTITUDE-AD and INTERCEPT-AD clinical study framework, and research on biomarkers and antibody selectivity.
Company news also covers Enhanced Brain Delivery (EBD™) work using transferrin-receptor-targeting blood-brain barrier technology, subcutaneous formulation research using ENHANZE® drug delivery technology, collaborations, conference presentations, operating results, financing activity, and management participation in health care and CNS investor events.
Acumen Pharmaceuticals has initiated dosing in its Phase 1 clinical trial, INTERCEPT-AD, for ACU193, a monoclonal antibody targeting toxic amyloid-beta oligomers in early Alzheimer’s patients. This trial aims to establish safety, pharmacokinetics, and target engagement and will enroll approximately 62 participants. The CEO expressed optimism regarding ACU193's potential to meet unmet medical needs in Alzheimer’s treatment, highlighting its unique mechanism compared to other monoclonal antibodies.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) reported Q2 2021 financial results, highlighting substantial progress in its clinical trial for ACU193, which targets toxic amyloid-beta oligomers linked to Alzheimer’s disease. The company closed an IPO in July 2021, raising approximately $168.6 million, boosting cash reserves to over $235 million. R&D expenses rose to $2.3 million for Q2 2021, while net losses surged to $61.4 million, largely due to non-cash expenses related to warrant liabilities. The ongoing Phase 1 trial, ACU-001, is expected to yield top-line results by the end of 2022.
Acumen Pharmaceuticals (Nasdaq: ABOS) has priced its upsized initial public offering (IPO) of 9,999,999 shares at $16.00 each, raising approximately $160 million before expenses. The offering will close on July 6, 2021, with shares expected to start trading on July 1, 2021. Acumen has granted underwriters a 30-day option for an additional 1,499,999 shares. The funds will support the development of ACU193, a therapy targeting Alzheimer’s disease. The company initiated a Phase 1 clinical trial for ACU193 in Q2 2021, with results expected by the end of 2022.